Legend Biotech (LEGN) Share-based Compensation (2020 - 2025)

Legend Biotech has reported Share-based Compensation for 6 years, with the latest figure at $15.0 million in Q3 2025.

• For the quarter ending Q3 2025, Share-based Compensation fell 0.64% year-over-year to $15.0 million; the trailing twelve-month figure through Sep 2025 stood at $64.8 million (down 4.65% YoY), and the FY2022 full-year result was $34.3 million, up 70.34% from the prior year.
• Share-based Compensation for Q3 2025 stood at $15.0 million, down from $18.7 million in the prior quarter.
• The five-year high for Share-based Compensation was $34.3 million in Q4 2022, with the low at $2.3 million in Q1 2021.
• Historically, Share-based Compensation has averaged $14.8 million across 5 years, with a median of $15.1 million in 2024.
• Annual changes were most pronounced in 2021 — Share-based Compensation surged 323.49% — and 2025, when it slipped 14.74%.
• Legend Biotech's Share-based Compensation stood at $20.2 million in 2021, then surged by 70.34% to $34.3 million in 2022, then tumbled by 63.96% to $12.4 million in 2023, then grew by 22.09% to $15.1 million in 2024, then retreated by 0.64% to $15.0 million in 2025.
• The last three Share-based Compensation figures came in at $15.0 million (Q3 2025), $18.7 million (Q2 2025), and $15.9 million (Q1 2025), per Business Quant data.